丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

丙型肝炎病毒核心抗原在血液透析患者中的检测和应用

Objective To investigate the utility of the HCV core antigen ELISA in the detection of HCV infection in hemodialysis patients and to compare with Anti-HCV antibodies 3rd generation ELISA.Methods Two hundred fifty hemodialysis patients were included in the study. Anti-HCV antibodies and total HCVcAg was determined by ELISA kits. HCV RNA was determined using reverse transeriptase polymerase chain reaction (RT-PCR) .Results Forty-three out of 250 (17.2%) patients were positive for anti-HCV antibodies and 18% WERE positive for HCVcAg. 13/250 (5.2%) were positive for HCVcAg but anti-HCV negative, All 13 were confirmed viremic by in-house nested RT-PCR leading to specificity of 100%. Viral load of (49258±28682) copies/ml were detected in HCVcAg positive cases was higher in comparison to (23938±10780) copies/ml in the anti-HCV positive group (P < 0.05). The viral load of 4 negative cases for HCVcAg assay but anti-HCV positive was 306±161 copies/rnl which was significantly lower in comparison to HCVcAg positive group (P < 0.001). Conclusion Detection of total HCVcAg together with anti-HCV will be useful for patients undergoing hemodialysis who have a longer window period due to immunosuppressed state. HCVcAg was compatible for the HCV RNA in serum and total HCVcAg ELISA is beth a cost-effective and a less labor-intensive alternative to PCR, enhancing its clinical utility.     

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases

To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody,detected by ELISAand indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates,in non-SARS subjects,114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients werecollected.The results of ELISA showed that among 114 sera from healthy controls,4 (3.5%) were positive ofSARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody;the specificity ofSARS-CoV-IgG antibody for SARS patients was 96.5%,but the specificity of both SARS-CoV-IgG and -IgMantibodies for SARS patients was 100%.In 58 cases with SLE,positive rates of SARS-CoV-IgG and -IgMantibodies were 32.8% (19/58) and 8.6% (5/58),respectively,in which 11 cases (19%) were positive of bothSARS-CoV-IgG and -IgM antibodies;in 10 cases with SS,positive rate of both SARS-CoV-IgG and -IgMantibodies was 10% (1/10);in 16 cases with MCTD,positive rate of SARS-CoV-IgG was 37.5% (6/16),positiverate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16);in 20 cases with RA,one case was positive(5%) of SARS-CoV-IgG.However,of all samples with positive SARS-CoV-IgG and -IgM antibodies forautoimmune diseases and healthy controls,SARS-CoV RNA and antibodies were all negative by RT-PCR andIFA.All sera for negative or positive ELISA results were also negative or positive results using ELISA withVero E6 cells lysates.These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detectSARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies innon-SARS diseases and healthy controls,and the false-positive reactions or cross-reactions were related to VeroE6 cell lysates and autoantibodies in non-SARS population.Cellular & Molecular Immunology.2004;1(4):304-307.